Commissioning for Quality in Rheumatoid Arthritis

Patient metric data collection form for INCIDENT / EARLY rheumatoid arthritis (RA)

Please use the correct form. There are separate forms for INCIDENT and PREVALENT patients

This data collection form is for use *only* in RA patients with INCIDENT / EARLY disease (i.e. patients ≤2 years from diagnosis)

Please review and complete every question using exception codes provided if needed

CQ RA Commissioning for Quality in Rheumatoid Arthritis

UNIT AND PATIENT DETAILS	
Q1	Unit (name)…… Age (circle applicable) <30 years 30–40 years 41–50 years 31–60 years 61–70 years >70 years Gender (circle applicable) Male Female

REFERRAL FOR SPECIALIST TREATMENT				
Q2	Date of referral …… First date with specialist …….. Date diagnosis of RA made ……			
	Was time from referral to treatment ≤ 6 weeks?	☐	☐	
If 'No', please briefly explain why				

DISEASE ACTIVITY ASSESSMENT					
Q3	Criteria	Yes	No	NM	*Exceptions – circle the code that applies. *See codes below*
3.1	Does the patient have DAS28>2.6[1]?	☐	☐	☐	*If 'No' go to question 4*
3.2	Has the patient been seen every 4–6 weeks? (See exception code A)	☐	☐		A
If 'No', please briefly explain why					
3.3	Was DAS28 assessed at every visit? (See exception code A)	☐	☐		A
If 'No', please briefly explain why					

NM = not measured

***Exception code:**

Code A: Circle code A if an active clinical decision was made not to do so.

CQRA Commissioning for Quality in Rheumatoid Arthritis

TREATMENT MODIFICATION					
Q4	**Criteria**	**Yes**	**No**	**NM**	***Exceptions – circle the code if applicable. *See codes below***
4.1	**Has the patient received rapid escalation of treatment in line with NICE guidance until clinical remission or DAS28 ≤2.6[1] is achieved? (See exception code A)**	☐	☐	☐	A
4.2	**Is the patient on biologics?**	☐	☐	***If 'No' go to question 5***	
4.3	**Has the patient achieved an adequate response within the first 6 months of initiating therapy (an improvement in DAS28 of 1.2 points or more) in line with NICE guidance[2]? (See exception codes A and B)** ***If 'Yes ' go to question 5***	☐	☐	☐	A B
4.4	**If the patient has not achieved a timely improvement in DAS28 of 1.2 points or more, has the patient been moved to the next treatment in the pathway according to NICE guidance[3,4]? (See exception codes A and B)**	☐	☐	☐	A B

NM = not measured

***Exception codes:**
Code A: Circle code A if an active clinical decision was made not to do so.
Code B: Circle code B if patient has been receiving biologics for less than 6 months.

CQRA Commissioning for Quality in Rheumatoid Arthritis

ANNUAL REVIEW#				
Q5	**Criteria**	**Yes**	**No**	***Exceptions – circle the code if applicable. *See code below***
Is it CLEARLY DOCUMENTED that the following actions have been carried out within the LAST 12 MONTHS:				
5.1	**Damage has been assessed, and functional ability measured (using, for example, the Health Assessment Questionnaire [HAQ])? (See exception code C)**	☐	☐	C
5.2	**The patient has been checked for the development of comorbidities (e.g., hypertension, ischaemic heart disease, osteoporosis, depression)? (See exception code C)**	☐	☐	C
5.3	**There was assessment of symptoms that suggest complications (e.g., vasculitis and disease of the cervical spine, lung, eyes)? (See exception code C)**	☐	☐	C
5.4	**Appropriate cross referral within the multidisciplinary team was organised? (See exception code C)**	☐	☐	C
5.5	**The patient has been asked about the impact of RA on their day-to-day experience of life (e.g. employment, social, sexual, functional activities of daily living)? (See exception code C)**	☐	☐	C

#NICE recommend an 'annual review' with each RA patient (NICE clinical guideline 79 – Rheumatoid arthritis: section 1.5.1.4)

***Exception code:**

Code C: Circle code C if patient is <1 year from diagnosis.

References

[1] Wells et al. Ann Rheum Dis 2009;68:954–960. In this paper DAS28 <2.6 is defined as the 'threshold for remission'. [2]NICE clinical guideline 79 – Rheumatoid arthritis. Available at: www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf (accessed August 2010).

[3]NICE technology appraisal guidance 195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. Available at: http://guidance.nice.org.uk/TA195/Guidance/pdf/English (accessed September 2010).

[4]NICE technology appraisal guidance 198: Tocilizumab for the treatment of rheumatoid arthritis. Available at: http://guidance.nice.org.uk/TA198/Guidance/pdf/English (accessed September 2010). Section 1.1.

Thank you for completing the form. Please return completed forms to Lindsey Bloomfield on behalf of the CQRA group (fax 01707 384123; email cqra@nras.org.uk)